ESCRS - FP79 - EVALUATION OF OCULAR SURFACE FOLLOWING PRESERFLO MICROSHUNT IMPLANTATION: FUNCTIONAL OUTCOMES AND QUALITY OF LIFE

EVALUATION OF OCULAR SURFACE FOLLOWING PRESERFLO MICROSHUNT IMPLANTATION: FUNCTIONAL OUTCOMES AND QUALITY OF LIFE

Published 2024 - 28th ESCRS Winter Meeting

Reference: FP79 | Type: Submission | DOI: 10.82333/gxns-qa47

Authors: Matteo Mario Carlà* 1 , Gloria Gambini 1 , Stanislao Rizzo 1

1Catholic University of the Sacred Heart - Agostino Gemelli Polyclinic Foundation,Rome,Italy

Purpose

This study aimed to evaluate the impact of PreserFlo Microshunt on the ocular surface, focusing on both objective and subjective parameters.

Setting

Prospective, monocentric, interventional study.

Methods

Prospective-observational study on 48 eyes undergoing PreserFlo Microshunt implantation, standalone or combined with phacoemulsification. At baseline (V0), 1-month (V1), 6-months (V6) and 12-months (V12) post-operative follow-ups, we performed Ocular Surface Disease Index (OSDI) questionnaire, Schirmer's test (ST), Tear-film break-up time (TBUT), fluoresceine staining (FS), tear osmolarity and minimum corneal epithelial thickness (Epi-ThkMIN.) measurements.

Results

OSDI score improved from 37.43±17.49 at V0, to 24.13±12.55 at V1 (p=0.003) and to 12.89±8.54 and 13.09±10.22 at V6 and V12 (p<0.0001). TBUT and ST, in a similar way, non-significantly increased at V1, but then improved at V6 and V12 (p<0.05 for both). Tear osmolarity significantly decreased from 308.2±7.3 mOsm/L at V0, to 303.3±8.2 mOsm/L, 295.6.2±7.0 mOsm/L and 297.6±6.8 mOsm/L at V1, V6 and V12 (p<0.05 for all). Epi-ThkMIN was stable when comparing V0 (44.9±5.7 µm) and V1 (p=0.28), and successively increased in V6 (47.8±5.5 µm, p=0.02) and V12 (48.0±3.6 µm, p=0.01). In subgroup analysis, OSDI score and tear osmolarity were significantly higher at V1 in combined group compared to standalone group (p=0.03 and p=0.02, respectively), but reaching comparable values in successive follow-ups. Further, Oxford scale grades for FS were significantly improved when comparing V0–V6 and V0–V12. 

Conclusion

PreserFlo implantation improved ocular surface subjective symptoms, increased TBUT and ST, and reduced FS, highlighting the potential benefits of this surgical intervention. Moreover, we reported significant improvements of tear osmolarity and corneal epithelium.